References
- Visser O, Schouten LJ, Elbertse BJJ. Feiten en Fabels Over Kanker in Nederland. Vereniging van Integrale Kankercentra, Utrecht (2000).
- Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 53,5-26 (2003).
- Devesa SS, Silverman DT, Young JL Jr et aL Cancer incidence and mortality trends among whites in the United States, 1947–84.j Natl Cancer Inst. 79(4), 701–770 (1987).
- Lokhorst HM, Sonneveld P, Cornelissen JJ et aL Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 23(4), 317–322 (1999).
- Huijgens PC, Dekker-Van Roessel HM, Jonkhoff AR et aL High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant27(9), 925–931 (2001).
- Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer 88(12 Suppl.), 3022–3032 (2000).
- Wisloff F, Gulbrandsen N, Nord E. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations. PharmacoEconomics 16(4), 329–341 (1999).
- Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl. J Med. 334(8), 488–493 (1996).
- Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment ofadvanced multiple myeloma patients reduces skeletal events. For the Myeloma Aredia Study Group. JOncol 16(2),593–602 (1998).
- •Shows the benefit of bisphosphonate therapy.
- Rosen LS, Gordon D, Kaminski M et aL Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. 7(5), 377–387 (2001).
- van Agthoven M, van Ineveld BM, de Boer MF et aL The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur. Cancer37 (17), 2204–2211 (2001).
- van Agthoven M, Groot MT, Verdonck LF et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplantation 30,243–251 (2002).
- van Agthoven M, Faber L, Uyl-de Groot CA. Diagnostiek, Behandeling en Follow-up van Het Intermediair en Hooggradig Non-Hodgkin Lymfoom. Institute for Medical Technology Assessment, Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands (2001).
- van Agthoven M, Faber LM, Uyl-de Groot CA et al. Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma. EuE j Haematol. 69(4), 213–220 (2002).
- van de Kuy A. Pharmacotherapeutical Compass 1998. Healthcare Board, Amstelveen, The Netherlands (1998).
- Coleman RE. Management of bone metastases. Oncologist 5(6), 463–470 (2000).
- •Provides an important perspective on the extent of skeletal morbidity associated with osteolytic lesions in pateints with multiple myeloma.
- Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Ann. Rev Med. 50,237–248 (1999).
- •Provides an overview of skeletal morbidity associated with multiple myeloma and the benefits of biphosphonate therapy.
- McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br. Haematol. 113(4), 1035–1043 (2001).
- •Shows the benefit of bisphosphonate therapy.
- Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet340, 1049–1052. Erratum in: Lancet 340,1420 (1992).
- Berenson JR, Hillner BE, Kyle RA et aL American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Clin. One& 20(17), 3719–3736 (2002).
- ••Provides guidelines for the use ofbisphosphonates to reduce skeletal morbidity associated with multiple myeloma.
- Buijt I, Ossenkoppele GJ, Uyl-de Groot CA, Huijgens PC. Costs of intensive treatment and follow-up of patients with multiple myeloma. Anti Cancer Drugs 9(10), 889–897 (1998).
- •• Relevant health economic analysis of multiple myeloma.
- Bruce NJ, McCloskey EV, Kanis JA, Guest JF. Economic impact of using clodronate in the management of patients with multiple myeloma. Br. I Haematol. 104(2), 358–364 (1999).
- •• Relevant health economic analysis of multiple myeloma, which accounts for the cost of skeletal-related events and oral clodronate.
- Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in The Netherlands. Bur. Ural. 43(3), 226–232 (2003).
- ••A similar analysis of the costs associatedwith skeletal complications in patients with prostate cancer treated in The Netherlands.
Websites
- Central Bureau of Statistics www.cbs.n1 (Accessed September 2004)
- Dutch Haemato-Oncology Association www.hovon.n1 (Accessed September 2004)